Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral · 1 trial · 1 indication
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Objective Response Rate (ORR) is defined as the proportion of subjects who achieve CR or PR after treatment via CD19/CD20 Dual-Target in vivo CAR-T Lentiviral cell infusion
| Arm | Type | Description |
|---|---|---|
| CD19/CD20 Dual-Target in vivo CAR-T Lentiviral | EXPERIMENTAL | Each subject will receive a single dose of CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product infusion. |
| Name | Type | Description |
|---|---|---|
| CD19/CD20 Dual-Target in vivo CAR-T Lentiviral | BIOLOGICAL | Prior to infusion of theCD19/CD20 Dual-Target in vivo CAR-T Lentiviral product, subjects may receive bridging therapy if needed. |
Inclusion Criteria: 1. Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's di...